SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D.
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company’s management will be attending and presenting at the H.C. Wainwright 28 th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.
Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments made to date to $50 million, a full return of NQ Project Phoebus, L.P.’s invested capital, with up to
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026 Phase 3 protocol of roxadustat for the treatment of anemia in
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further